Preferential Rights Issue 2024
Background and rationale of the rights issue
The Board of Directors have on April 26, 2024, decided on a on a rights issue of shares with pre-emption rights for the shareholders of approximately SEK 34.4 million (the “Rights Issue”). For each share owned on the record date June 3, 2024, the holder will receive one (1) subscription right. Seven (7) subscription rights will entitle the holder to subscribe for six (6) shares. The subscription price per share amounts to SEK 0.90. The subscription period for the Rights Issue will run from and including June 5, 2024 until and including June 20, 2024.
Alzinova’s primary focus is the development of ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer’s disease. The vaccine candidate, ALZ-101, has demonstrated promising results in phase 1b trials, showing favourable safety and tolerability data. Additionally, an in-depth analysis shows a positive trend in biomarkers associated with Alzheimer’s disease. In parallel with the phase 1b-study, Alzinova is actively preparing for phase 2 study.
Alzinova is also developing ALZ-201, an oligomer-specific monoclonal antibody that can be used as a stand-alone disease-modifying therapy or complement to ALZ-101 for the treatment of Alzheimer’s disease. The antibody is currently undergoing preclinical studies.
The proceeds, after issuing costs, from the Rights Issue shall primarily be used for:
- Production of ALZ-101 for phase 2 trial, approximately 29 percent.
- Expansion of the phase 1b study through Part A2 and Part B, regulatory and administrative costs for phase 2 preparations, approximately 20 percent.
- Strengthening of Alzinova’s working capital for research and development, approximately 40 percent.
- Patent and patent development for ALZ-101 and ALZ-201, as well as business development, approximately 11 percent.
Summarizing terms of the rights issue:
- Subscription period: June 5, 2024 – June 20, 2024.
- Trade in unit rights: June 5, 2024 – June 17, 2024.
- Subscription with preferential rights: For each share owned on the record date June 3, 2024, the holder will receive one (1) subscription right. Seven (7) subscription rights will entitle the holder to subscribe for six (6) shares. The subscription price per share amounts to SEK 0.90.
- Subscription price: The subscription price per share amounts to SEK 0.90.
- Issue proceeds: Upon full subscription in the Rights Issue, the Company receives approximately SEK 34.4 million before issuing costs.
Subscription commitments and underwriting commitments: The rights issue is covered to 100 percent through subscription commitments and underwriting commitments.
Links:
- Prospectus, 3 June 2024 (Swedish)
- Application form / Anmälningssedel med teckningsrätter (Swedish)
- Application form / Anmälningssedel utan företräde (Swedish)
- Articles of Association / Bolagsordning, in Swedish
- Financial advisor – Mangold AB
- Annual Report 2023 (Swedish)
- Annual Report 2023 (English)
- Interim report Q1 2024 (Swedish)
- Interim report Q1 2024 (English)
- Registration certificate Alzinova AB, in Swedish
Press releases:
- The Board of Directors resolves on a rights issue of shares of approximately SEK 34.4 million, April 26, 2024
- Alzinova participates in several conferences and investor meetings in the spring of 2024, May 13, 2024
- First patient dosed with a higher dose of ALZ-101 in the phase 1b study, May 21, 2024
- Alzinova publishes prospectus, June 3, 2024
- The subscription period in Alzinovas rights issue of shares, June 5, 2024
- New positive safety review for Alzinova’s phase 1b study, June 10, 2024
- Alzinova’s rights issue oversubscribed, June 25, 2024
Q&A session at Redeye with CEO Kristina Torfgård
Our CEO, Kristina Torfgård recently sat down with Redeye for an insightful interview discussing the upcoming rights issue and the latest progress within the company. Check out the full interview below!
Alzinova - Healthcare Webinar at Penser Access by Carnegie
Our CEO, Kristina Torfgård recently presented at Penser Access by Carnegie. View the full presentation below.
Alzinova presented in investor pitch by BioStock
View the full presentation in Swedish below.
Alzinova at Aktiedagarna in Stockholm
CEO Kristina Torfgård presented Alzinova at Aktiespararnas’ event Aktiedagarna. View the full presentation in Swedish below.
Information will follow in English below.
Informationen på denna del av webbsidan får inte offentliggöras, publiceras eller distribueras, direkt eller indirekt, inom eller till USA, Kanada, Australien, Nya Zeeland, Sydafrika, Sydkorea, Schweiz, Singapore, Japan, Hongkong, Ryssland, Belarus eller någon annan jurisdiktion där sådan åtgärd skulle vara olaglig, föremål för legala restriktioner eller kräva registrering eller andra åtgärder än de som följer av svensk rätt.
Informationen på denna webbsida utgör inte ett erbjudande om, eller inbjudan att, förvärva eller teckna några uniträtter, betalda tecknade units (BTU), eller andra värdepapper i bolaget i någon jurisdiktion, varken från Alzinova eller någon annan, där ett sådant erbjudande skulle vara olagligt eller kräver registrering eller annan åtgärd. Ingen åtgärd har vidtagits och åtgärder kommer inte att vidtas för att tillåta ett erbjudande till allmänheten i några andra jurisdiktioner än Sverige. Ett erbjudande att teckna units i Alzinova kommer endast att ske genom det prospekt som Alzinova avser att offentliggöra omkring den 4 februari 2026. Inga units eller andra värdepapper i Alzinova har registrerats, och inga units eller andra värdepapper kommer att registreras, enligt den vid var tid gällande United States Securities Act från 1933 (“Securities Act”) eller värdepapperslagstiftningen i någon delstat eller annan jurisdiktion i USA och får inte erbjudas, säljas eller på annat sätt överföras, direkt eller indirekt, i eller till USA, förutom i enlighet med ett tillämpligt undantag från, eller i en transaktion som inte omfattas av, registreringskraven i Securities Act och i enlighet med värdepapperslagstiftningen i relevant delstat eller annan jurisdiktion i USA.
I Storbritannien riktas informationen på denna webbsida enbart till personer i Storbritannien som är (i) professionella investerare som faller inom den vid var tid gällande Article 19(5) i U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“Ordern”) eller (ii) subjekt med hög nettoförmögenhet och andra personer som detta meddelande lagligen kan riktas till, vilka omfattas av Article 49(2)(a)-(d) i Ordern (alla sådana personer benämns tillsammans “Relevanta Personer”). Personer som inte är Relevanta Personer får inte agera på eller förlita sig på informationen som finns på denna del av webbsidan. En investering eller investeringsåtgärd som denna information avser är enbart möjlig för Relevanta Personer och kommer endast att fullföljas avseende Relevanta Personer.
Åtkomst till informationen och dokumenten på denna webbsida kan vara olaglig i vissa jurisdiktioner. Personer som önskar åtkomst till informationen som finns tillgänglig på denna webbsida måste först försäkra sig om att de inte är föremål för lokala lagar eller regler som förbjuder eller begränsar deras rätt till åtkomst till denna webbsida eller som kräver registrering eller godkännande av deras eventuella förvärv av värdepapper. Alzinova AB tar inget ansvar för överträdelser av tillämpliga lagar och regler av någon person. Om du inte är behörig att ta del av informationen och dokumenten på webbsidan, eller vid tvivel om du är behörig, vänligen lämna denna webbsida.
Även om Alzinova AB bedömer att informationen på webbsidan är korrekt och fullständig per dagen för dess tillgängliggörande, och även om Alzinova AB kan komma att publicera ny information från tid till annan, åtar sig Alzinova AB ingen skyldighet att uppdatera eller korrigera sådan information och avsäger sig uttryckligen alla sådana skyldigheter.
Genom att samtycka och ta del av den information och de dokument som detta samtycke ger åtkomst till bekräftar du att du i) har läst och förstått informationen ovan, ii) samtycker till att bindas av dessa villkor och följa samtliga restriktioner, iii) enligt tillämpliga lagar och regler är behörig att fortsätta till webbsidan utan att bolaget måste vidta ytterligare åtgärder, iv) inte kommer att överföra eller på annat sätt skicka information som finns på webbsidan till någon person i USA eller till publikationer med allmän spridning i USA.
English
The information on this section of the website may not be disclosed, published, or distributed, directly or indirectly, within or to the United States, Canada, Australia, New Zealand, South Africa, South Korea, Switzerland, Singapore, Japan, Hong Kong, Russia, Belarus, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or require registration or other measures beyond those required under Swedish law.
The information on this website does not constitute an offer to, or an invitation to, acquire or subscribe for any unit rights, paid subscribed units (BTUs), or other securities in the company in any jurisdiction, whether from Alzinova or any other party, where such an offer would be unlawful or require registration or other measures. No action has been taken, nor will any action be taken, to permit a public offering in any jurisdictions other than Sweden. An offer to subscribe for units in Alzinova will only be made through the prospectus that Alzinova intends to publish around 4 February 2026. No units or other securities in Alzinova have been registered, and no units or other securities will be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold, or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable securities laws of any state or other jurisdiction in the United States.
In the United Kingdom, the information on this website is directed only at persons who are (i) professional investors falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), or (ii) high net worth entities and other persons to whom this communication may lawfully be made, falling within Article 49(2)(a)–(d) of the Order (all such persons together being referred to as “Relevant Persons”). Persons who are not Relevant Persons must not act on or rely on the information contained in this section of the website. Any investment or investment activity to which this information relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
Access to the information and documents on this website may be unlawful in certain jurisdictions. Persons who wish to access the information available on this website must first satisfy themselves that they are not subject to local laws or regulations that prohibit or restrict their right of access to this website or that require registration or approval of any acquisition of securities by them. Alzinova AB assumes no responsibility for any violation of applicable laws or regulations by any person. If you are not authorised to access the information and documents on this website, or if you are in any doubt as to whether you are authorised, please leave this website.
Although Alzinova AB considers the information on the website to be accurate and complete as of the date it is made available, and although Alzinova AB may publish new information from time to time, Alzinova AB undertakes no obligation to update or correct such information and expressly disclaims any such obligation.
By consenting to and accessing the information and documents to which this consent grants access, you confirm that you (i) have read and understood the information above, (ii) agree to be bound by these terms and to comply with all restrictions, (iii) are, under applicable laws and regulations, authorised to proceed to the website without the company being required to take any further action, and (iv) will not transfer or otherwise send any information contained on the website to any person in the United States or to publications with general circulation in the United States.
Accept
